Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics (PSTV)
:PSTV
Holding PSTV?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.4Last Year’s EPS
-0.55Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2018
|% Change Since: -7.14%
|Next Earnings Date:Aug 14, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant clinical progress and grant support as highlights, while financial challenges such as decreased cash reserves and increased operating losses as lowlights.Company Guidance
During the Plus Therapeutics Third Quarter 2024 Earnings Call, guidance was provided on several key metrics and strategic developments. The company highlighted progress in their ReSPECT-LM trial for leptomeningeal metastases, announcing the transition to a modified Cohort 6 dose of 75 millicuries after treating a patient with a substantial 66 millicuries dose of Rhenium (186Re) Obisbemeda. They also shared that 21 patients have been treated, with three receiving compassionate use doses. Additionally, Plus Therapeutics plans to expand this trial to a multiple dose administration trial, having obtained FDA agreement for a multiple dose escalation protocol. In terms of financials, the company reported a cash balance of $4.8 million as of September 2024, with plans to receive additional grant advances. The total operating loss for the year was $10.8 million, attributed mainly to increased spending on the ReSPECT-LM trial. Plus is also preparing for a limited commercial release of its CNSide cerebrospinal fluid assay platform in the U.S. by January 2025, following a CLIA certificate of compliance expected in Q1 2025. The company is targeting grant funding of at least $10 million per year and expects to complete enrollment in their ReSPECT-GBM Phase II trial by mid-2025.Progress in the ReSPECT-LM Trial
The trial reached an agreement with the FDA to proceed under a multiple dose escalation protocol, with doses up to 44 millicuries found to be safe and well tolerated. Further data from Cohorts 1 through 4 showed a 53% reduction in circulating tumor cells on average at day 28 post-treatment, and a median overall survival of 12 months compared to a historical consensus of 4 months.
Expansion of Clinical Trial Sites
Added Ohio State University and North Shore Hospital to support Phase II enrollment and potentially a pivotal trial, with Phase II completion expected by mid-2025.
Financial Strength and Grant Support
The company received $4.4 million in grant revenue year-to-date, with expectations of $6 million to $7 million in 2024. They have significant grant support from CPRIT and the Department of Defense, totaling approximately $27 million including committed grant revenue.
---
PSTV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PSTV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $1.26 | $1.17 | -7.14% |
| Aug 14, 2024 | $1.42 | $1.40 | -1.41% |
| May 15, 2024 | $2.32 | $2.25 | -3.02% |
| Mar 05, 2024 | $2.18 | $1.94 | -11.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Plus Therapeutics (PSTV) report earnings?
Plus Therapeutics (PSTV) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Plus Therapeutics (PSTV) earnings time?
Plus Therapeutics (PSTV) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PSTV EPS forecast?
PSTV EPS forecast for the fiscal quarter 2024 (Q4) is -0.4.
---